HLA-G gene editing: a novel therapeutic alternative in cancer immunotherapy
M. B. Palma, D. Tronik-Le Roux, G. Amin, S. Castaneda, A. M. Mobbs, M. A. Scarafia, A. La Greca, M. Daouya, I. Poras, A. M. Inda, L. N. Moro, E. D. Carosella, M. N. Garcia, S. G. Miriuka
This study uses CRISPR/Cas9 to downregulate HLA-G in tumor cell lines, showing enhanced immune response and proposing gene editing as a novel immunotherapy approach.
bioRxiv · Jan 21, 2021 · PreprintCancer Biology